检索结果-南通市图书馆

Chinese Journal of Cancer Research 2017年第2期29卷 156-165页

作者： Heng Li Wenjie Xiong Huimin Liu Shuhua Yi Zhen Yu Wei Liu Rui Lyu Tingyu Wang dehui zou Zengjun Li Lugui Qiu State Key Laboratory of Experimental Hematology Institute of Hematology and Blood Disease Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300020 China

Objective： This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia （CLL） and a 17p deletion （17p-） and identify the predictive factors within this subgroup. Methods： The sample of patients with CLL were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 1 lq22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p- were retrospectively collected and analyzed. Results： The overall response rate （ORR） in patients with a 17p- was 56.9%, and patients with a high percentage of 17p- （defined as more than 25% of cells harbouring a 17p-） had a lower ORR. The median overall survival （OS） in patients with a 17p- was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality （median 162.0 months, P〈0.001）. Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase （LDH）, B symptoms, unmutated IGHVand a high percentage of 17p-. Conclusions： These results indicated that patients with a 17p- CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.

关键词： 17p deletion chronic lymphocytic leukemia (CLL) fluorescent in situ hybridization (FISH) del 17pin CLL

在线全文

学校读者我要写书评

暂无评论

普乐沙福用于外周血干细胞动员的研究进展

中国肿瘤临床 2021年第11期48卷 541-546页

作者：邹德慧邱录贵中国医学科学院血液病医院(中国医学科学院血液学研究所) 实验血液学国家重点实验室国家血液系统疾病临床医学研究中心天津市300020

大剂量化疗联合自体外周血干细胞(peripheral blood stem cell,PBSC)移植是淋巴瘤和多发性骨髓瘤(multiple myeloma,MM)的有效治疗手段。PBSC的常规动员方案包括粒细胞集落刺激因子(granulocyte colony-stimulating factor,G-CSF)单用或联合化疗。部分患者使用常规动员方案无法采集到目标剂量的CD34+细胞,无法进行造血干细胞(hematopoietic stem cell,HSC)移植治疗。因此,针对动员不佳患者以及降低具有危险因素患者动员失败的风险,根据个体情况有效调整动员策略十分必要。普乐沙福是一种新型动员剂,联合G-CSF可显著提高CD34+细胞采集量,降低动员失败率的同时缩短采集天数,进而提高自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)效率,改善患者长期预后。本文对普乐沙福在PBSC动员的研究进展进行综述,旨在探讨普乐沙福适宜的动员人群、干预时机和路径,以优化PBSC的动员策略。

关键词：造血干细胞移植外周血干细胞动员普乐沙福

Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenstr（o）m macroglobulinemia

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2014年第12期127卷 2327-2331页

作者： Yi Shuhua Cui Rui Li Zengjun An Gang Qi Junyuan zou dehui Zhang Peihong Chen Huishu Wang Jianxiang Chang Hong Qiu Lugui State Key Laboratory of Experimental Hematology Institute of Hematology and Blood Disease HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeTianjin 300020China Department of Hematology Tianjin First Center HospitalTianjin 300192China Division of Cellular and Molecular Biology Toronto GeneralHospital Research Institute Department of Laboratory Medicine& Pathobiology University of Toronto Toronto MSG2C4 Canada

Background Waldenstr（o）m macroglobulinemia （WM） is an uncommon lymphoid *** characteristics and prognosis of WM have never been systematically studied in the *** We analyzed the clinical characteristics and the prognostic factors of 90 Chinese WM patients,and compared them with the Western *** The median age was 62 years old with a male-to-female ratio of *** most common symptoms at diagnosis were fatigue （77.8％） and bleeding （20％）,while only 6 patients （6.7％） were *** the univariate analysis,age ＞62 years,thrombocytopenia,leucopenia,cytopenias ≥2,and high risk on the international prognostic scoring system for WM were the adverse risk factors,but only age ＞62 years and ≥2 cytopenias were the independent prognostic factors in the multivariate *** age ＜62 years and ≥2 cytopenias,three significantly different prognostic groups could been distinguished,with 5-year overall survival of 71.6％,48.6％,and 17.0％（P ＜0.001）.Conclusion Distinct characteristics exist in WM in China compared to the West and we describe a new simple prognostic model for newly diagnosed WM patients.

关键词： clinical characteristics prognosis Waldenstr(o)m macroglobulinemia cytopenias

基于晶体三极管的不同中子能谱等效性实验研究

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

核技术 2014年第6期37卷 60-65页

作者：鲁艺邱东邹德惠荣茹中国工程物理研究院核物理与化学研究所绵阳621900

辐射损伤等效性系数是评价不同中子能谱对样品的实验损伤差异的关键。利用晶体管直流增益的倒数与中子注量呈线性关系这一特点,采用参数一致性好的硅双极晶体管3DG121C作为位移损伤探测器,通过在线监测晶体管直流增益随累积中子注量的变... 详细信息

辐射损伤等效性系数是评价不同中子能谱对样品的实验损伤差异的关键。利用晶体管直流增益的倒数与中子注量呈线性关系这一特点,采用参数一致性好的硅双极晶体管3DG121C作为位移损伤探测器,通过在线监测晶体管直流增益随累积中子注量的变化,分别获得了CFBR-II堆两个特定位置的损伤常数,推导出了不同中子能谱间的辐射损伤等效系数。结果表明,CFBR-II不同位置的辐射损伤没有显著差异。

关键词：辐射效应损伤常数等效性系数硅双极晶体管快中子临界装置

在线全文

学校读者我要写书评

暂无评论

至骨针法探析

中医学报 2021年第10期36卷 2098-2101页

作者：邹德辉华北理工大学中医学院河北唐山063000

至骨针法是以触至病所、针至病所、意至病所、动至病所、气至病所为特色,主要包括直刺至骨法、斜刺至骨法、飞针至骨法、弹针至骨法。选穴以全身骨骼及软骨边缘的经穴、奇穴、阿是穴和全息穴为主。操作时,先触诊定位,针尖需抵达骨面或... 详细信息

至骨针法是以触至病所、针至病所、意至病所、动至病所、气至病所为特色,主要包括直刺至骨法、斜刺至骨法、飞针至骨法、弹针至骨法。选穴以全身骨骼及软骨边缘的经穴、奇穴、阿是穴和全息穴为主。操作时,先触诊定位,针尖需抵达骨面或针身贴骨进针。病灶骨面重在针至病所、松解粘连;远端骨缘腧穴常重压或捻转刺激,配合主被动导引活动,导气至病所。主要治疗急慢性疼痛、功能障碍性疾病、神志性疾病、脑源性疾病等。

关键词：至骨针法骨膜经穴奇穴阿是穴全息穴直刺至骨法斜刺至骨法飞针至骨法弹针至骨法

程序性死亡受体1抑制剂在霍奇金淋巴瘤中的应用

在线全文

学校读者我要写书评

暂无评论

白血病．淋巴瘤 2021年第8期30卷 449-454页

作者：山丹丹刘薇邹德慧中国医学科学院血液病医院(中国医学科学院血液学研究所)实验血液学国家重点实验室国家血液系统疾病临床医学研究中心天津300020

程序性死亡受体1(PD-1)抑制剂在霍奇金淋巴瘤中具有独特的作用机制和较好疗效。多个PD-1抑制剂单药已被批准用于经典型霍奇金淋巴瘤患者较晚期的挽救治疗,其与其他小分子靶向药物、免疫活性药物或细胞毒性药物等联合应用可进一步提高疗... 详细信息

程序性死亡受体1(PD-1)抑制剂在霍奇金淋巴瘤中具有独特的作用机制和较好疗效。多个PD-1抑制剂单药已被批准用于经典型霍奇金淋巴瘤患者较晚期的挽救治疗,其与其他小分子靶向药物、免疫活性药物或细胞毒性药物等联合应用可进一步提高疗效,较传统方案的安全性更好,也被尝试用于复发难治患者及一线治疗。另外,9P24.1扩增、PD-1配体表达、循环肿瘤DNA水平等可能是预测PD-1抑制剂疗效的潜在生物标志物。

关键词：霍奇金淋巴瘤免疫检查点抑制剂药物疗法,联合分子靶向治疗程序性死亡受体1

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newlydiagnosed multiple myeloma

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2023年第14期136卷 1744-1746页

作者： Wenqiang Yan Huishou Fan Jingyu Xu Jiahui Liu Lingna Li Chenxing Du Shuhui Deng Weiwei Sui Yan Xu dehui zou Lugui Qiu Gang An State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood DiseasesHaihe Laboratory of Cell EcosystemInstitute of Hematology&Blood Diseases HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeTianjin 300020China Tianjin Institutes of Health Science Tianjin 301600China

To the Editor:Multiple myeloma(MM)is a plasma cell disorder characterized by heterogeneous features.^([1])Accurate risk stratification could predict diverse prognoses of patients with myeloma and attain risk-adapted therapy to extend their ***,the European Myeloma Network(EMN)conducted a large retrospective analysis involving more than 7000 patients with myeloma and developed a new risk model defined as the Second Revision of International Staging System(R2-ISS),with excellent risk distribution among patients enrolled in clinical trials.^([2])The R2-ISS stratifications were based on weighted risk scores of different prognostic factors:ISS II 1.0 point,ISS III 1.5 points,del(17p)1.0 point,elevated lactate dehydrogenase(LDH)1.0 point,t(4;14)1.0 point,and 1q21+0.5 points.

关键词： patients myeloma elevated

Cytogenetic aberrations of lymphoplasmacytic lymphoma/ Waldenström’s macroglobulinemia in Chinese patients

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2023年第10期136卷 1240-1242页

作者： Wenjie Xiong Tingyu Wang Ying Yu Yang Jiao Jiawen Chen Yi Wang Chengwen Li Rui Lyu Qi Wang Wei Liu Weiwei Sui Gang An dehui zou Lugui Qiu Shuhua Yi State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood DiseasesHaihe Laboratory of Cell EcosystemInstitute of Hematology&Blood Diseases HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeTianjin 300020China Tianjin Institutes of Health Science Tianjin 301600China

To the Editor:As a rare indolent B cell non-Hodgkin lymphoma,lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia(LPL/WM)has unique clinical and biological characteristics.[1]However,due to the difficulties in obtaining tumor metaphase for karyotyping and slow cell proliferation,only very few studies have detected the cytogenetic aberration of LPL/WM.[2,3]In addition,6q deletion is the most common cytogenetic aberration in WM,with an incidence rate of about 50%.[2]Nevertheless,other cytogenetic aberrations remain largely unclear,and the prognostic role of cytogenetic aberrations needs to be further *** the present study,we systematically analyzed 305 LPL/WM cases in China,focusing on the characteristics and cytogenetic aberrations in Chinese patients.

关键词： lymphoma patients globulin

在线全文

学校读者我要写书评

暂无评论

2016版WHO淋巴肿瘤分类修订解读

中华医学杂志 2016年第42期96卷 3365-3369页

作者：易树华邹德慧 Ken He Young 邱录贵中国医学科学院血液病医院淋巴瘤诊疗中心天津300020 美国MD Anderson癌症中心血液病理系

自2008年第4版世界卫生组织（WHO）造血与淋巴组织肿瘤分类（以下称2008版）发布以来，淋巴组织肿瘤的临床与基础研究取得巨大进展，有些类型的淋巴瘤需要重新定义，同时也报道一些新的亚型。

关键词：淋巴组织肿瘤肿瘤分类 WHO 解读修订世界卫生组织淋巴瘤

Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第13期137卷 1620-1622页

作者： Hesong zou Wei Liu Yi Wang Dandan Shan Ting Xie Ru Li Huimin Liu Wenyang Huang Mingwei Fu Tingyu Wang Rui Lyu Shuhui Deng Weiwei Sui Yan Xu Shuhua Yi Gang An Lugui Qiu dehui zou State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood DiseasesHaihe Laboratory of Cell EcosystemInstitute of Hematology&Blood Diseases HospitalChinese Academy of Medical Science&Peking Union Medical CollegeTianjin 300020China Tianjin Institutes of Health Science Tianjin 301600China

To the Editor:Diffuse large B-cell lymphoma(DLBCL)exhibits clinical significance and biological *** the last two decades,rituximab with cyclophosphamide,doxorubicin,vincristine,and prednisone(R-CHOP)has substantially improved outcomes for DLBCL ***,approximately one-third of DLBCL cases continue to experience disease progression,resulting in long-term survival ranging from 50%to 60%.[1]Efforts to improve DLBCL patient outcomes by modifying R-CHOP dosing schedules have yielded limited success,and the addition of new drugs has benefited only specific patient ***,intensive immunochemotherapy(IIC)has demonstrated promise and cost-effectiveness in recent *** regimen of dose-adjusted etoposide.

关键词： CHOP drugs chemotherapy